All the news Showing 10 of 20 articles from: Side effectsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis Keith Alcorn / 30 April 2013 Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have only a moderate chance of being ... Adherence to hepatitis C treatment: unravelling the complexities Rob Camp / 13 December 2012 Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ... Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir Liz Highleyman / 13 November 2012 Chronic hepatitis C patients treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anaemia by either ribavirin dose reduction or addition of erythropoietin (EPO) without compromising treatment effectiveness, researchers ... European guidelines on management of mental health for people with hepatitis C published Michael Carter / 16 October 2012 European investigators have developed a consensus statement on hepatitis C and mental health. Published in the online edition of the Journal of Hepatology, the wide-ranging document assesses evidence concerning the effect of hepatitis C ... Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir Liz Highleyman / 11 May 2012 Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th ... Depression and pegylated interferon: doctors look at screening strategies and treatment Michael Carter / 09 May 2012 Patients with hepatitis C should be carefully evaluated for symptoms of depression before and during pegylated interferon-based therapy, investigators write in the International Journal of Interferon, Cytokine and Mediator Research. The authors also highlighted ... Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment Keith Alcorn / 20 April 2012 A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate ... Common side-effects of hepatitis C protease inhibitors: clinical management advice published Michael Carter / 20 January 2012 The addition of the protease inhibitors telaprevir or boceprevir to hepatitis C treatment regimens increases the risk of anaemia, according to a review article published in Liver International. The author also found that ... Coffee consumption reduces side-effects in people on hepatitis C treatment Gus Cairns / 14 September 2011 Drinking three or more cups of coffee a day reduced the incidence of self-reported side-effects by more than 80% compared to non-coffee drinkers in people co-infected with hepatitis C and HIV who were taking ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive